Co. Mcdonnell et al., Effect of multimodality therapy on circulating vascular endothelial growthfactor levels in patients with oesophageal cancer, BR J SURG, 88(8), 2001, pp. 1105-1109
Background: Angiogenesis is critical for tumour growth and metastasis. The
switch to the angiogenic phenotype depends on the net balance between posit
ive and negative angiogenic factors released by the tumour. It was hypothes
ized that patients with oesophageal cancer would express raised serum level
s of vascular endothelial growth factor (VEGF) which would return to normal
values with neoadjuvant chemoradiotherapy.
Methods: Forty-four patients with oesophageal cancer who were selected for
treatment with neoadjuvant chemoradiotherapy had blood samples taken before
treatment, during chemoradiotherapy, before operation, on days 1, 3 and 5
after surgery, and 3 months after resection. Serum levels of VEGF were meas
ured. Values were correlated with response to treatment. Controls were pati
ents who were undergoing surgery for non-malignant conditions.
Results: Serum VEGF levels were raised in patients with oesophageal cancer
compared with age-matched controls (mean 247 versus 1157 pg/ml; P < 0.01).
VEGF levels were unaffected by neoadjuvant treatment but fell significantly
on the first day after operation (652 versus 1057 pg/ml before operation;
P < 0.05). No decrease occurred in control patients. VEGF levels had return
ed to preoperative levels by day 5. A similar postoperative rise in VEGF le
vels was seen in the control subjects (1194 pg/ml on day 5 versus 71 pg/ml
before operation; P = 0.001). There was no correlation between VEGF level a
nd response to treatment or tumour stage. VEGF levels had decreased signifi
cantly at 3 months following tumour resection (594 versus 1558 pg/ml on day
5; P = 0.03).
Conclusion: VEGF levels are raised in patients with oesophageal cancer and
are unaltered by neoadjuvant treatment, suggesting an additional source oth
er than tumour cells for this proangiogenic agent.